VYGR — Voyager Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$3.45
+$0.02 (+0.58%)
Voyager Therapeutics Inc (VYGR) is a biotechnology company listed on NASDAQ. It is led by Alfred W. Sandrock Jr., M.D., Ph.D., based in 75 Hayden Avenue, Lexington, MA, United States, 02421, with about 141 employees. Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Latest reported VYGR revenue for 2025-09-30 was $13.4M. Net income was -$92.3M. Revenue was up 157.0% from 2025-06-30 to 2025-09-30. VYGR currently screens at market cap $225.4M.
Use this VYGR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the VYGR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the VYGR SEC filings page. Lician reads the product cache first so this HTML stays unique to Voyager Therapeutics Inc even when a live quote feed is slow.
About Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
VYGR Key Statistics
Market Cap
$225.37M
Volume
306,272
Previous Close
$3.44
Day Range
$3.45 – $3.56
P/B Ratio
1.26
EPS
-$1.13
Revenue
$80.00M
Net Income
-$65.00M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-68.0%
Profit Margin
-81.3%
Employees
141
VYGR Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $80.00M | $250.01M | $40.91M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$65.00M | $132.33M | -$46.41M |
| EPS (Diluted) | -$1.13 | $2.97 | -$1.21 |
Total Assets
$393.05M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$71.37M
Operating Cash Flow
-$15.31M
Free Cash Flow
$0.00
Voyager Therapeutics Inc Company Information
- President, CEO & Director
- Alfred W. Sandrock Jr., M.D., Ph.D.
- Headquarters
- 75 Hayden Avenue, Lexington, MA, United States, 02421
- Website
- www.voyagertherapeutics.com
- Phone
- 857 259 5340
- IPO / Founded
- 2015-11-11
- Sector
- Healthcare
- Industry
- Biotechnology